vir一季报乙肝新药消息

newchinabok

https://investors.vir.bio/news-r ... and-reports-first-1

newchinabok

Hepatitis B Virus (HBV)

At its recent Hepatitis Portfolio R&D Day, the Company announced encouraging data from the first cohort (Part A) of the Phase 2 MARCH (Monoclonal Antibody siRNA Combination against Hepatitis B) trial, which suggest that VIR-2218 and VIR-3434 are additive in reducing hepatitis B surface antigen (HBsAg), with no drug-related safety signals reported to date.
In 2022, the Company expects data readouts from multiple trials evaluating VIR-2218 and VIR-3434:
Additional data from the Phase 1 monotherapy trial of VIR-3434 and Phase 2 monotherapy trial of VIR-2218 are expected in the second quarter of 2022.
Additional data from the Phase 2 trial of VIR-2218 in combination with PEG-IFN-α are expected in the second half of 2022.
Additional data from the first cohort (Part A) of the MARCH trial evaluating safety, pharmacokinetics and HBsAg suppression are expected in the second half of 2022. Note, with clinical trial sites in Ukraine and Moldova, the Company continues to monitor the war in Ukraine closely to determine any potential impact on trial timing.
Initial data from the Phase 2 trial evaluating VIR-2218 in combination with BRII-179, an investigational T cell vaccine, for the potential treatment of chronic HBV infection, led by Brii Biosciences, are expected in the second half of 2022.
The Company expects to initiate a Phase 2 platform trial of VIR-2218 in combination with VIR-3434 in viremic patients (THRIVE/STRIVE sub-protocols) in the second half of 2022